Frazier Life Sciences Management, L.P. - INTELLIA THERAPEUTICS INC ownership

INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 285 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.

Quarter-by-quarter ownership
Frazier Life Sciences Management, L.P. ownership history of INTELLIA THERAPEUTICS INC
ValueSharesWeighting
Q1 2024$5,603,347
-9.8%
203,6840.0%0.24%
-28.9%
Q4 2023$6,210,325
-3.6%
203,6840.0%0.33%
-22.4%
Q3 2023$6,440,488
-22.5%
203,6840.0%0.43%
-13.7%
Q2 2023$8,306,234
+9.4%
203,6840.0%0.50%
-9.8%
Q1 2023$7,591,303
+6.8%
203,6840.0%0.55%
+24.4%
Q4 2022$7,106,535
-37.7%
203,6840.0%0.44%
-49.7%
Q3 2022$11,398,000
+8.1%
203,6840.0%0.88%
-11.8%
Q2 2022$10,543,000
-28.8%
203,6840.0%1.00%
-21.1%
Q1 2022$14,802,000203,6841.26%
Other shareholders
INTELLIA THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 744,160$54,078,0005.79%
Discovery Value Fund 986,173$71,665,0005.28%
Ally Bridge Group (NY) LLC 60,000$4,360,0003.23%
MPM BioImpact LLC 159,409$11,584,0003.11%
ARK Investment Management 8,981,029$652,651,0002.72%
Elmwood Wealth Management, Inc. 67,599$4,912,0002.52%
Nikko Asset Management Americas, Inc. 2,872,269$192,442,0001.41%
Frazier Life Sciences Management, L.P. 203,684$14,802,0001.26%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 111,440$8,098,0001.22%
Merlin Capital, Inc 11,575$841,0001.11%
View complete list of INTELLIA THERAPEUTICS INC shareholders